A survey of yeast genomic assays for drug and target discovery

Pharmacology and Therapeutics

Volumn 127, Issue 2, 2010, Pages 156-164

  Smith, Andrew M ^a,b   Ammar, Ron ^a,b   Nislow, Corey ^a,b   Giaever, Guri ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemical biology; Chemical genomics; Drug action; Drug target; Yeast

Indexed keywords

ALVERINE CITRATE; CALYCULIN A; CERIVASTATIN; CYCLOHEXIMIDE; CYCLOSPORIN A; ERODOXIN; FENPROPIMORPH; FLUCONAZOLE; METHOTREXATE; MEVINOLIN; RAPAMYCIN; TACROLIMUS; THEOPALAUAMIDE; TUNICAMYCIN; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT;

DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION PROFILING; GENOMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; FUNGAL GENOME; GENETICS; HUMAN; PROCEDURES;

ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE EXPRESSION PROFILING; GENOME, FUNGAL; GENOMICS; HUMANS; SACCHAROMYCES CEREVISIAE;

EID: 77954212737     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.04.012     Document Type: Review

References (118)

1. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 1980, 77(7):3957-3961.
2. Apostol B., Greer C.L. Copy number and stability of yeast 2 mu-based plasmids carrying a transcription-conditional centromere. Gene 1988, 67(1):59-68.
3. Arnoldo A., Curak J., Kittanakom S., Chevelev I., Lee V.T., Sahebol-Amri M., et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 2008, 4(2):e1000005.
4. Bader G.D., Heilbut A., Andrews B., Tyers M., Hughes T., Boone C. Functional genomics and proteomics: Charting a multidimensional map of the yeast cell. Trends in Cell Biology 2003, 13(7):344-356.
5. Baetz K., McHardy L., Gable K., Tarling T., Reberioux D., Bryan J., et al. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci U S A 2004, 101(13):4525-4530.
6. Birrell G.W., Giaever G., Chu A.M., Davis R.W., Brown J.M. A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity. Proc Natl Acad Sci U S A 2001, 98(22):12608-12613.
7. Bischoff H., Angerbauer R., Boberg M., Petzinna D., Schmidt D., Steinke W., et al. Preclinical review of cerivastatin sodium - A step forward in HMG-CoA reductase inhibition. Atherosclerosis 1998, 139(Suppl 1):S7-S13.
8. Breslow D.K., Cameron D.M., Collins S.R., Schuldiner M., Stewart-Ornstein J., Newman H.W., et al. A comprehensive strategy enabling high-resolution functional analysis of the yeast genome. Nat Methods 2008, 5(8):711-718.
9. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56(1):100-104.
10. Butcher E.C., Berg E.L., Kunkel E.J. Systems biology in drug discovery. Nat Biotechnol 2004, 22(10):1253-1259.
11. Butcher R.A., Bhullar B.S., Perlstein E.O., Marsischky G., LaBaer J., Schreiber S.L. Microarray-based method for monitoring yeast overexpression strains reveals small-molecular targets in the TOR pathway. Nat Chem Biol 2006, 2:103-109.
12. Carroll S.Y., Stirling P.C., Stimpson H.E., Giesselmann E., Schmitt M.J., Drubin D.G. A yeast killer toxin screen provides insights into a/b toxin entry, trafficking, and killing mechanisms. Dev Cell 2009, 17(4):552-560.
13. Cayley P.J., Dunn S.M., King R.W. Kinetics of substrate, coenzyme, and inhibitor binding to Escherichia coli dihydrofolate reductase. Biochemistry 1981, 20(4):874-879.
14. Chan J.N., Nislow C., Emili A. Recent advances and method development for drug target identification. Trends Pharmacol Sci 2009.
15. Chang M., Bellaoui M., Boone C., Brown G.W. A genome-wide screen for methyl methanesulfonate-sensitive mutants reveals genes required for S phase progression in the presence of DNA damage. Proc Natl Acad Sci U S A 2002, 99(26):16934-16939.
16. Chervitz S.A., Aravind L., Sherlock G., Ball C.A., Koonin E.V., Dwight S.S., et al. Comparison of the complete protein sets of worm and yeast: Orthology and divergence. Science 1998, 282(5396):2022-2028.
17. Chiu M.I., Katz H., Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994, 91(26):12574-12578.
18. Cirstea D., Vallet S., Raje N. Future novel single agent and combination therapies. Cancer J 2009, 15(6):511-518.
19. Costanzo M., Baryshnikova A., Bellay J., Kim Y., Spear E.D., Sevier C.S., et al. The genetic landscape of a cell. Science 2010, 327(5964):425-431.
20. Costanzo M., Giaever G., Nislow C., Andrews B. Experimental approaches to identify genetic networks. Curr Opin Biotechnol 2006, 17(5):472-480.
21. Cowen L.E., Steinbach W.J. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008, 7(5):747-764.
22. Crouzet M., Perrot M., Nogueira M., Begueret J. Genetic and biochemical analysis of cycloheximide resistance in the fungus Podospora anserina. Biochem Genet 1978, 16(3-4):271-286.
23. Dixon S.J., Costanzo M., Baryshnikova A., Andrews B., Boone C. Systematic mapping of genetic interaction networks. Annu Rev Genet 2009, 43:601-625.
24. Dixon S.J., Stockwell B.R. Identifying druggable disease-modifying gene products. Curr Opin Chem Biol 2009, 13(5-6):549-555.
25. Dorer R.K., Zhong S., Tallarico J.A., Wong W.H., Mitchison T.J., Murray A.W. A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol 2005, 15(11):1070-1076.
26. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2(5):561-566.
27. Ericson E., Gebbia M., Heisler L.E., Wildenhain J., Tyers M., Giaever G., et al. Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet 2008, 4(8):e1000151.
28. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
29. Frye S.V. The art of the chemical probe. Nat Chem Biol 2010, 6(3):159-161.
30. Giaever G., Chu A.M., Ni L., Connelly C., Riles L., Veronneau S., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002, 418(6896):387-391.
31. Giaever G., Flaherty P., Kumm J., Proctor M., Nislow C., Jaramillo D.F., et al. Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A 2004, 101(3):793-798.
32. Giaever G., Shoemaker D.D., Jones T.W., Liang H., Winzeler E.A., Astromoff A., et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 1999, 21(3):278-283.
33. Goh K.I., Cusick M.E., Valle D., Childs B., Vidal M., Barabasi A.L. The human disease network. Proc Natl Acad Sci U S A 2007, 104(21):8685-8690.
34. Goodman L.S., Hardman J.G., Limbird L.E., Gilman A.G. Goodman and Gilman's the pharmacological basis of therapeutics 2001, McGraw-Hill, New York. 10th ed.
35. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253(5022):905-909.
36. Higgins M.J., Graham S.J. Intellectual property. Balancing innovation and access: Patent challenges tip the scales. Science 2009, 326(5951):370-371.
37. Hillenmeyer M.E., Fung E., Wildenhain J., Pierce S.E., Hoon S., Lee W., et al. The chemical genomic potrait of yeast: Uncovering a phenotype for all genes. Science 2008, 320(5874):362-365.
38. Ho C.H., Magtanong L., Barker S.L., Gresham D., Nishimura S., Natarajan P., et al. A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat Biotechnol 2009, 27(4):369-377.
39. Hoon S., Smith A.M., Wallace I.M., Suresh S., Miranda M., Fung E., et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol 2008, 4(8):498-506.
40. Hopkins A.L., Groom C.R. The druggable genome. Nat Rev Drug Discov 2002, 1(9):727-730.
41. Hu Y., Rolfs A., Bhullar B., Murthy T.V., Zhu C., Berger M.F., et al. Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae. Genome Res 2007, 17(4):536-543.
42. Hughes T.R. Yeast and drug discovery. Funct Integr Genomics 2002, 2(4-5):199-211.
43. Hughes T.R., Marton M.J., Jones A.R., Roberts C.J., Stoughton R., Armour C.D., et al. Functional discovery via a compendium of expression profiles. Cell 2000, 102(1):109-126.
44. Johnston M. A model fungal gene regulatory mechanism: The GAL genes of Saccharomyces cerevisiae. [Review]. Microbiological Reviews 1987, 51(4):458-476.
45. Jones G.M., Stalker J., Humphray S., West A., Cox T., Rogers J., et al. A systematic library for comprehensive overexpression screens in Saccharomyces cerevisiae. Nat Methods 2008, 5(3):239-241.
46. Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., et al. Predicting new molecular targets for known drugs. Nature 2009, 462(7270):175-181.
47. Kohlwein S.D. Obese and anorexic yeasts: Experimental models to understand the metabolic syndrome and lipotoxicity. Biochim Biophys Acta 2010, 1801(3):222-229.
48. Kuo S.C., Lampen J.O. Tunicamycin - an inhibitor of yeast glycoprotein synthesis. Biochem Biophys Res Commun 1974, 58(1):287-295.
49. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935.
50. Lamesch P., Li N., Milstein S., Fan C., Hao T., Szabo G., et al. hORFeome v3.1: A resource of human open reading frames representing over 10,000 human genes. Genomics 2007, 89(3):307-315.
51. Lazar J.D., Wilner K.D. Drug interactions with fluconazole. Rev Infect Dis 1990, 12(Suppl 3):S327-S333.
52. Lee W., St Onge R.P., Proctor M., Flaherty P., Jordan M.I., Arkin A.P., et al. Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet 2005, 1(2):e24.
53. Lehar J., Stockwell B.R., Giaever G., Nislow C. Combination chemical genetics. Nat Chem Biol 2008, 4(11):674-681.
54. Leppert G., McDevitt R., Falco S.C., Van Dyk T.K., Ficke M.B., Golin J. Cloning by gene amplification of two loci conferring multiple drug resistance in Saccharomyces. Genetics 1990, 125(1):13-20.
55. Li J.W., Vederas J.C. Drug discovery and natural products: End of an era or an endless frontier?. Science 2009, 325(5937):161-165.
56. Li X., Zolli-Juran M., Cechetto J.D., Daigle D.M., Wright G.D., Brown E.D. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem Biol 2004, 11(10):1423-1430.
57. Liebler D.C., Guengerich F.P. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005, 4(5):410-420.
58. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66(4):807-815.
59. Lum P.Y., Armour C.D., Stepaniants S.B., Cavet G., Wolf M.K., Butler J.S., et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004, 116(1):121-137.
60. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137(5):835-848.
61. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837.
62. Mandal S., Moudgil M., Mandal S.K. Rational drug design. Eur J Pharmacol 2009, 625(1-3):90-100.
63. Marton M.J., DeRisi J.L., Bennett H.A., Iyer V.R., Meyer M.R., Roberts C.J., et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998, 4(11):1293-1301.
64. McGary K.L., Park T.J., Woods J.O., Cha H.J., Wallingford J.B., Marcotte E.M. Systematic discovery of nonobvious human disease models through orthologous phenotypes. Proc Natl Acad Sci U S A 2010, 107(14):6544-6549.
65. McManus K.J., Barrett I.J., Nouhi Y., Hieter P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A 2009, 106(9):3276-3281.
66. Miyahara K., Mizunuma M., Hirata D., Tsuchiya E., Miyakawa T. The involvement of the Saccharomyces cerevisiae multidrug resistance transporters Pdr5p and Snq2p in cation resistance. FEBS Lett 1996, 399(3):317-320.
67. Miyano S. Research in computational molecular biology: 9th annual International Conference, RECOMB 2005, Cambridge, MA, USA, May 14-18, 2005: proceedings 2005, Springer, Berlin.
68. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124(6):1283-1298.
69. Molin M., Norbeck J., Blomberg A. Dihydroxyacetone kinases in Saccharomyces cerevisiae are involved in detoxification of dihydroxyacetone. J Biol Chem 2003, 278(3):1415-1423.
70. Mushegian A.R., Bassett D.E., Boguski M.S., Bork P., Koonin E.V. Positionally cloned human disease genes: Patterns of evolutionary conservation and functional motifs. Proc Natl Acad Sci U S A 1997, 94(11):5831-5836.
71. Osborn M.J., Miller J.R. Rescuing yeast mutants with human genes. Brief Funct Genomic Proteomic 2007, 6(2):104-111.
72. Parsons A.B., Brost R.L., Ding H., Li Z., Zhang C., Sheikh B., et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 2004, 22(1):62-69.
73. Parsons A.B., Lopez A., Givoni I.E., Williams D.E., Gray C.A., Porter J., et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 2006, 126(3):611-625.
74. Pathania R., Zlitni S., Barker C., Das R., Gerritsma D.A., Lebert J., et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol 2009, 5(11):849-856.
75. Paulsen I.T., Sliwinski M.K., Nelissen B., Goffeau A., Saier M.H. Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae. FEBS Lett 1998, 430(1-2):116-125.
76. Pena-Castillo L., Hughes T.R. Why are there still over 1000 uncharacterized yeast genes?. Genetics 2007, 176(1):7-14.
77. Pierce S.E., Davis R.W., Nislow C., Giaever G. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat Protoc 2007, 2(11):2958-2974.
78. Pierce S.E., Fung E.L., Jaramillo D.F., Chu A.M., Davis R.W., Nislow C., et al. A unique and universal molecular barcode array. Nat Methods 2006, 3(8):601-603.
79. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12(11):1294-1300.
80. Provart N.J., McCourt P. Systems approaches to understanding cell signaling and gene regulation. Curr Opin Plant Biol 2004, 7(5):605-609.
81. Quon K., Kassner P.D. RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets 2009, 13(9):1027-1035.
82. Richardson K., Cooper K., Marriott M.S., Tarbit M.H., Troke P.F., Whittle P.J. Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 1990, 12(Suppl 3):S267-S271.
83. Rine J., Hansen W., Hardeman E., Davis R.W. Targeted selection of recombinant clones through gene dosage effects. Proc Natl Acad Sci U S A 1983, 80:6750-6754.
84. Rix U., Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009, 5(9):616-624.
85. Rock F.L., Mao W., Yaremchuk A., Tukalo M., Crepin T., Zhou H., et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007, 316(5832):1759-1761.
86. Rual J.F., Hill D.E., Vidal M. ORFeome projects: Gateway between genomics and omics. Curr Opin Chem Biol 2004, 8(1):20-25.
87. Rual J.F., Hirozane-Kishikawa T., Hao T., Bertin N., Li S., Dricot A., et al. Human ORFeome version 1.1: A platform for reverse proteomics. Genome Res 2004, 14(10B):2128-2135.
88. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78(1):35-43.
89. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24(3):236-244.
90. Schlabach M.R., Luo J., Solimini N.L., Hu G., Xu Q., Li M.Z., et al. Cancer proliferation gene discovery through functional genomics. Science 2008, 319(5863):620-624.
91. Scholl C., Frohling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137(5):821-834.
92. Schreiber S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287(5460):1964-1969.
93. Schuldiner M., Collins S.R., Thompson N.J., Denic V., Bhamidipati A., Punna T., et al. Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile. Cell 2005, 123(3):507-519.
94. Sidhu S.S., Bader G.D., Boone C. Functional genomics of intracellular peptide recognition domains with combinatorial biology methods. Curr Opin Chem Biol 2003, 7(1):97-102.
95. Silva J.M., Li M.Z., Chang K., Ge W., Golding M.C., Rickles R.J., et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 2005, 37(11):1281-1288.
96. Silva J.M., Marran K., Parker J.S., Silva J., Golding M., Schlabach M.R., et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008, 319(5863):617-620.
97. Smith A.M., Heisler L.E., Mellor J., Kaper F., Thompson M.J., Chee M., et al. Quantitative phenotyping via deep barcode sequencing. Genome Res 2009, 19(10):1836-1842.
98. Snyder M., Gallagher J.E. Systems biology from a yeast omics perspective. FEBS Lett 2009, 583(24):3895-3899.
99. Song C.M., Lim S.J., Tong J.C. Recent advances in computer-aided drug design. Brief Bioinform 2009, 10(5):579-591.
100. Sopko R., Huang D., Preston N., Chua G., Papp B., Kafadar K., et al. Mapping pathways and phenotypes by systematic gene overexpression. Mol Cell 2006, 21(3):319-330.
101. St Onge R.P., Mani R., Oh J., Proctor M., Fung E., Davis R.W., et al. Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat Genet 2007, 39(2):199-206.
102. Stockwell B.R. Exploring biology with small organic molecules. Nature 2004, 432(7019):846-854.
103. Suganuma M., Fujiki H., Furuya-Suguri H., Yoshizawa S., Yasumoto S., Kato Y., et al. Calyculin A, an inhibitor of protein phosphatases, a potent tumor promoter on CD-1 mouse skin. Cancer Res 1990, 50(12):3521-3525.
104. Teotico D.G., Babaoglu K., Rocklin G.J., Ferreira R.S., Giannetti A.M., Shoichet B.K. Docking for fragment inhibitors of AmpC beta-lactamase. Proc Natl Acad Sci U S A 2009, 106(18):7455-7460.
105. Tong A.H., Boone C. Synthetic genetic array analysis in Saccharomyces cerevisiae. Methods Mol Biol 2006, 313:171-192.
106. Tong A.H., Evangelista M., Parsons A.B., Xu H., Bader G.D., Page N., et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 2001, 294(5550):2364-2368.
107. Tong A.H., Lesage G., Bader G.D., Ding H., Xu H., Xin X., et al. Global mapping of the yeast genetic interaction network. Science 2004, 303(5659):808-813.
108. Tugendreich S., Perkins E., Couto J., Barthmaier P., Sun D., Tang S., et al. A streamlined process to phenotypically profile heterologous cDNAs in parallel using yeast cell-based assays. Genome Res 2001, 11(11):1899-1912.
109. Wagner B.K., Clemons P.A. Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic profiling. Curr Opin Chem Biol 2009, 13(5-6):539-548.
110. Wehner E.P., Rao E., Brendel M. Molecular structure and genetic regulation of SFA, a gene responsible for resistance to formaldehyde in Saccharomyces cerevisiae, and characterization of its protein product. Mol Gen Genet 1993, 237(3):351-358.
111. Winzeler E.A., Shoemaker D.D., Astromoff A., Liang H., Anderson K., Andre B., et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999, 285:901-906.
112. Workman C.T., Mak H.C., McCuine S., Tagne J.B., Agarwal M., Ozier O., et al. A systems approach to mapping DNA damage response pathways. Science 2006, 312(5776):1054-1059.
113. Xu D., Sillaots S., Davison J., Hu W., Jiang B., Kauffman S., et al. Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans. J Biol Chem 2009, 284(29):19754-19764.
114. Yan Z., Costanzo M., Heisler L.E., Paw J., Kaper F., Andrews B.J., et al. Yeast barcoders: A chemogenomic application of a universal donor-strain collection carrying bar-code identifiers. Nat Methods 2008, 5(8):719-725.
115. Yu H., Braun P., Yildirim M.A., Lemmens I., Venkatesan K., Sahalie J., et al. High-quality binary protein interaction map of the yeast interactome network. Science 2008, 322(5898):104-110.
116. Yu L., Lopez A., Anaflous A., El Bali B., Hamal A., Ericson E., et al. Chemical-genetic profiling of imidazo[1, 2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells. PLoS Genet 2008, 4(11):e1000284.
117. Zhang N., Osborn M., Gitsham P., Yen K., Miller J.R., Oliver S.G. Using yeast to place human genes in functional categories. Gene 2003, 303:121-129.
118. Zhu H., Bilgin M., Bangham R., Hall D., Casamayor A., Bertone P., et al. Global analysis of protein activities using proteome chips. Science 2001, 293:2101-2105.